The
U-M pediatric oncologists have expertise in the management of all childhood cancers and are world-renowned experts in the areas listed below.
|
Special Expertise |
· Blood and Marrow Transplant · Brain Tumors · Leukemia · Long-Term Follow-Up · Lymphomas · Neuroblastoma · Radiation Oncology · Retinoblastoma · Sarcomas · Wilms' Tumor |
|---|
|
Ages Treated |
Children of all ages are treated. |
|---|---|
|
General Information Hot Line |
800.865.1125, 9:00 AM to 4:30 PM EST, Monday through Friday. |
|
Physician-to-Physician Communications |
800.962.3555 |
|
Location |
|
|
Facility Description |
The C.S. Mott Children's Hospital combines the most advanced medical technology with an inviting, very human setting and a full spectrum of amenities for patients and their families. The décor is brightly colored and the equipment child-sized. Each hospital room at the Children's Hospital contains sleeping accommodations for overnight guests. |
|
Travel Assistance |
Social workers arrange transportation for patients. Chartered aircraft are available to transport patients throughout the |
|
Lodging |
Social workers assist in lodging arrangements for families. Families needing lodging and who cannot afford it can contact the Social Work Department at 734.764.3140 for information about assistance. The U-M has arrangements with local hotels and motels for discounted accommodations. The Guest Assistance Program can suggest a number of convenient, reasonably priced hotels, some with shuttle service to and from the A Ronald McDonald House is nearby. This temporary residence serves as an inexpensive "home away from home" for the parents and families of children being treated at the The "Med-Inn" is a hotel connected directly to the |
|
Social Support |
All social workers are Master's level professionals with expertise in assisting those faced with health issues. |
|
Financial Assistance |
Social work assists families in obtaining financial assistance from Children's Special Health Services. CSHS will help pay health care costs for patients that need assistance. Social work also arranges transportation and meal support for patients when needed. |
|
Home Health Care |
U-M has a non-profit home health agency, "Home Med." The program actively participates in the development of outpatient protocols for the treatment of pediatric malignancies. In addition, the center works with other home care agencies in |
|
Director of Division Pediatric Hematology/Oncology |
Steven Pipe, MD |
|---|---|
|
Clinical Director of Bone Marrow Transplant |
John Levine, MD |
|
Director of Outpatient Pediatric Oncology Services |
Ray Hutchinson, MD |
|
Multidisciplinary Teams |
U-M is a national leader in the multidisciplinary approach to cancer care. The multidisciplinary team includes highly trained physicians, four pediatric oncology nurse practitioners and pediatric bone marrow transplant nurses who provide ongoing care to patients. The specialists involved depend on the individual needs of each patient. The multidisciplinary clinic held for pediatric brain tumors permits patients and their families to consult with a group of medical specialists including neurologists, radiation oncologists, neurosurgeons, hematologist/ oncologists, and experts in rehabilitative medicine. |
|
Cooperative Group Membership |
Children's Oncology Group (COG) Blood and Marrow Transplantation Clinical Trials Network (BMTCTN) |
|
Cooperative Group Activities |
The pediatric hematology/oncology faculty and nurse practitioners play an integral role in COG committees specifically for the development and implementation of treatment protocols and basic research studies in oncology. Staff participate in COG committees and strategy groups on the following diseases: · Acute lymphoblastic leukemia · Hodgkin's disease · Non-Hodgkin's lymphoma · Neuroblastoma · Brain tumors In addition, BMT faculty serves in leadership positions in COG (Vice-chair Stem Cell Transplant Committee), NIH BMT Clinical Trials Network (Chair), and Pediatric Blood and Marrow Transplant Consortium (Executive Committee). |
|
Average Number of Pediatric Clinical Trials |
60 |
|
Pediatric Clinical Trial Coordinator |
Margaret Barnich, CCRA, for Pediatric Hematology/Oncology |
U-M has the largest research effort in Pediatric Oncology in
The bone marrow transplant research portfolio is broad and includes:
· Novel agents for the treatment and prevention of graft-vs.-host disease
· Tumor lysate pulsed dendritic cell cancer vaccine for patients with high risk solid tumors
· Treatment of refractory neuroblastoma with MIBG, chemotherapy, and autologous bone marrow transplantation
· The oncology division has a research protocol for refractory neuroblastoma using Velcade
Blood and Marrow Transplant
Since 1990, U-M has performed bone marrow transplantation for the treatment of leukemia and other hematological malignancies, solid tumors, and a variety of other cancer-related diseases. U-M performs autologous, related, unrelated, and cord blood allogenic transplants. A comprehensive strategy aims to improve outcomes by both decreasing transplant toxicities and reducing the risk of cancer recurrence. For example, to better treat the often lethal pulmonary related complication of idiopathic pneumonia syndrome, U-M researchers developed a TNF-inhibition treatment that has demonstrated a 67% reduction in mortality. Likewise, because relapse is the primary cause of treatment failure for patients with high-risk neuroblastoma, U-M researchers have developed trials that utilize pre-transplant MIBG therapy (a novel method for delivery of high-dose radiation to metastatic foci of neuroblastoma disease) or post-transplant immunotherapy with a tumor-lysate pulsed dendritic cell cancer vaccine. The bone marrow transplant program is accredited by FACHT and is approved by the National Marrow Donor Program.
Brain Tumors
Using a multidisciplinary approach, each patient is assigned a team consisting of a child neurologist trained in neuro-oncology, a pediatric neurosurgeon, radiation oncologists, nurse practitioners, and social workers. The division is actively involved in the evaluation of new drug protocols.
Leukemia
U-M researchers have contributed to the declining mortality rate for childhood cancers. For example, U-M led a national trial establishing the value of delayed intensification for the management of childhood ALL in the
Long-Term Follow-Up
This program is designed to meet the needs of adolescents and young adults diagnosed with cancer as children, who are now five years past all therapy. Staff members are involved in the Childhood Cancer Survivors Study Group to examine the long-term effects of treatment on childhood cancer survivors, in conjunction with the
Neuroblastoma
Faculty are national leaders in the generation of clinical guidelines and clinical research trials for the treatment of neuroblastoma.
Radiation Oncology
U-M has one of very few "racetrack microtrons" in the country. The microtron is able to focus radiation onto a treatment field that conforms more closely to the shape of the tumor, thus sparing adjacent normal tissue.
|
|
0-1 |
2-5 |
6-12 |
13+ |
|---|---|---|---|---|
|
Percent Treated |
1% |
18% |
35% |
45% |
|
No. of Inpatient Beds |
No. of Oncologists |
No. of Admissions |
Average Length of Stay (days) |
No. of New Outpatients |
Total Outpatient Visits |
|---|---|---|---|---|---|
|
16 |
1 17 |
1, 1,121 |
7. 7.01 |
4 433 |
5, 5,640 |
|
No. of Inpatient Beds |
No. of Transplanters |
Average Length of Stay (days) |
Number of Bone Marrow Transplants |
|---|---|---|---|
|
8 |
5 |
32.2 |
43 |
| Quick Links |
|
|
About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us
275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved